NICHD Neonatal Research Network
Trial Pipeline
Neonatal Platelet Transfusion Threshold Trial
NCT06676904
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
NCT06679855
Follow-up Visit of High Risk Infants
NCT00009633
Generic Database of Very Low Birth Weight Infants
NCT00063063
The Budesonide in Babies (BiB) Trial
NCT04545866
Cycled Phototherapy
NCT03927833
Management of the PDA Trial
NCT03456336
Transfusion of Prematures Trial
NCT01702805
Hydrocortisone for BPD
NCT01353313
Cerebral Function Monitoring in Premature Infants
NCT00873847
Physiologic Definition of Bronchopulmonary Dysplasia
NCT01223287
Delivery Room CPAP in Extremely Low Birth Weight Infants
NCT01223274
Inflammatory Cytokines Associated With Perinatal Brain Injury
NCT01035697
Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants
NCT00005775
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
NCT01203501
Development of Standards for the New Ballard Maturation Score
NCT01203449
Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection
NCT01203345
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 5 |
What the Pipeline for NICHD Neonatal Research Network Shows
According to the ClinicalTrials.gov registry, NICHD Neonatal Research Network is linked to 44 US clinical trials across every stage of research activity. Of those, 31 studies are currently recruiting — about 70% of the sponsor's indexed portfolio — and 10 are already marked complete, representing roughly 23% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for NICHD Neonatal Research Network reports 5 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for NICHD Neonatal Research Network is Infant, Small for Gestational Age with 13 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.